Study study type PathologyT1T0Patientssample sizesROB Results

ovarian cancer (OC) ovarian cancer (OC)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
AGO-OVAR 2.29/ENGOT-ov34, 2024
  NCT03353831
RCTovarian cancer (OC)atezolizumabSocrecurrent ovarian, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after completing platinum-based chemotherapy or 3rd relapse285 / 289NA
inconclusive
  • inconclusive 17 % decrease in deaths (OS) (PE)
  • inconclusive 13 % decrease in progression or deaths (PFS) (PE)

metastatic/advanced OC (mOC) - 1st line (L1) metastatic/advanced OC (mOC) - 1st line (L1)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
AGO-OVAR 2.29/ENGOT-ov34, 2024
  NCT03353831
RCTovarian cancer (OC)atezolizumabSocrecurrent ovarian, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after completing platinum-based chemotherapy or 3rd relapse285 / 289NA
inconclusive
  • inconclusive 17 % decrease in deaths (OS) (PE)
  • inconclusive 13 % decrease in progression or deaths (PFS) (PE)